News Immunotech Biopharm Ltd

Equities

6978

KYG4721A1004

Market Closed - Hong Kong S.E. Other stock markets 04:09:00 2024-05-03 EDT			5-day change	1st Jan Change
3.43 ^HKD	+0.88%		+3.63%	-31.40%

03-29	Immunotech Biopharm Posts Nearly 335 Million Yuan Loss in 2023	MT
03-28	Immunotech Biopharm Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Immunotech Biopharm Posts Nearly 335 Million Yuan Loss in 2023	03-29	MT
Immunotech Biopharm Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Immunotech Biopharm Obtains Clinical Trial Nod in China for Leukemia Drug	02-19	MT
Immunotech Biopharm Receives an Approval of the Investigational New Drug Application for Phase I Clinical Trial from the Centre for Drug Evaluation of the National Medical Products Administration for the aT19 Injection	02-19	CI
Immunotech Biopharm Ltd Announces First Patient Enrolled in the Phase II Clinical Trialfor Car-T-19 Injection	01-03	CI
Chinese Drug Regulator Accepts Immunotech Biopharm's Application for AT19 Injection	11-27	MT
Immunotech Biopharm Enrolls First Patient in Clinical Trial of Lymphoma Drug	11-07	MT
Immunotech Biopharm Ltd Completes the First Patient Enrolment for its Phase I Clinical Trial for the Denocabtagene Ciloleucel Injection	11-07	CI
China Grants Breakthrough Therapy Designation to Immunotech's Liver Cancer Medication; Shares Fall 5%	23-09-06	MT
Immunotech Biopharm Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-27	CI
Immunotech Biopharm Ltd Announces Board Changes	23-08-27	CI
Immunotech Biopharm Ltd Announces Director Changes	23-03-26	CI
Immunotech Biopharm Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-24	CI
Immunotech Biopharm Obtains China Clinical Trial Approval for Lymphoma Treatment	23-03-22	MT
Immunotech Biopharm Ltd Obtains the Clinical Approval for the Denocabtagene Ciloleucel Injection from the National Medical Products Administration	23-03-21	CI
Immunotech Biopharm Extends Completion Date of Convertible Bond Sale	23-01-26	MT
Immunotech Biopharm’s New Drug Application for Lymphoma Injection Accepted by Chinese Regulator	22-12-29	MT
Immunotech Biopharm Ltd. Receives Acceptance Notice for the Investigational New Drug Application for the Denocabtagene Ciloleucel Injection	22-12-28	CI
Immunotech Biopharm Shareholders to Meet on Convertible Bond Issuance	22-12-16	MT
Immunotech Biopharm Ltd announced that it expects to receive CNY 300 million in funding from Tianjin Tasly Pharmaceutical Co., Ltd., Investment Arm	22-10-27	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Immunotech Biopharm Ltd

Equities

6978

KYG4721A1004

Summary

Filters